01 — At a Glance
The Mess Is Real. The Fixes Are Coming. Maybe.
- 52-Week High / Low₹241 / ₹143
- Q3 FY26 Revenue₹2,140 Cr
- Q3 FY26 Net Loss-₹136 Cr
- 9M FY26 Revenue₹6,117 Cr
- 9M FY26 Net Loss-₹317 Cr
- Book Value₹60.7
- Price to Book2.56x
- EV/EBITDA19.4x
- Net Debt~₹4,200 Cr
- Debt/Equity0.60x
Bleeding Out: Piramal Pharma just reported ₹136 crore quarterly loss on ₹2,140 crore revenue. Year-to-date down 3–4% YoY. ROCE at 6.45% — lower than an FD rate in a high-interest environment. Three named headwinds: inventory destocking in a big on-patent product, weak biotech funding destroying CDMO order inflows, and regulatory delays tanking inhalation anesthesia exports. But management just dropped a $100M+ strategic bet (Kenalog acquisition + $90M capex), betting that the turnaround is real. The stock has been down 22.5% in one year. Either the market is giving it away, or the company is actually broken.
02 — Introduction
Welcome to the Pharma Roller Coaster Nobody Wanted a Ticket For
Piramal Pharma is living proof that you can own three decent businesses and still somehow manage to lose money. A CDMO arm. A critical-care injectable brand portfolio. A breakout consumer healthcare segment that’s actually printing money. You’d think that’s a diversified dream portfolio, right? Wrong.
FY26 has been absolute carnage. Down 3–4% YoY in revenues. Burning ₹317 crore in losses across the first nine months. ROCE sitting at a pathetic 6.45%. The stock has cratered 22.5% over one year. Management keeps blaming temporary headwinds — destocking here, weak biotech funding there, regulatory delays everywhere. Yet here they are, dropping $35 million upfront (plus up to $65M contingent) on a Kenalog acquisition. Translation: they genuinely believe the turnaround is coming. Or they’re panicking. Sometimes it’s hard to tell.
Founded in 1988 through acquisition of Nicholas Laboratories, Piramal went through years of M&A, sold off its domestic formulations business to Abbott for $3.7 billion in 2010, spun out diagnostics to SRL. Now it’s a global play with 15 CDMO sites, hospital critical-care generics, and a sub-₹2,000 crore consumer healthcare empire. The company has never been profitable on a consolidated basis in living memory. Seriously. Check FY24 (₹18 crore profit). FY25 (₹91 crore profit). FY26 YTD: ₹317 crore loss. One quarter of stupidity can wipe out four quarters of decent earnings.
But the interesting bit? Management is convinced that once the inventory dust settles, once biotech funding picks back up, and once those regulatory approvals for Sevoflurane exports happen, they’ll be laughing all the way to the bank. We’ll see if that’s conviction or delusion.
Concall Notes (Jan 2026): “Significant improvement in RFPs” and “good pickup in orders” acknowledged by management. But also: “we are further from” the long-range plan “than we would like.” Translation: We’re hoping, but we’re not that confident.
03 — Business Model: Three Bets, One Portfolio
The Tripartite Dream That’s Actually Just Three Headaches
Piramal Pharma operates three distinct segments, each with its own drama. CDMO is the revenue engine: 58% of sales in FY24, ₹1,166 crore in Q3 alone. The company has 15 manufacturing sites globally — four in North America, two in Europe, nine in India. They serve ~500 clients across pharma and biotech. The pitch is outsourced manufacturing at scale for regulated markets. The reality? Dependent on biopharma funding cycles that are currently as reliable as a monsoon forecast.
Complex Hospital Generics (CHG) is the next act: 30% of revenues. Inhalation anesthesia dominates — 67% of CHG sales. They own Sevoflurane manufacturing in the US (45% market share) and are ramping production in India (Digwal plant). Intrathecal Baclofen (spinal cord therapy) is their 78% US market share crown jewel. These are margins-rich products with moats — but regulatory delays in exporting Sevoflurane from India have been a nightmare.
Consumer Healthcare is the only segment actually growing properly (+20% in Q3, +16% in 9M). Little’s baby products, Lacto Calamine, Tetmosol, Polycrol. ₹1,000 crore in annual sales from brands that didn’t exist 16 years ago. E-commerce is up 50%+ YoY. The segment is self-funded, asset-light, and recently hit breakeven. This is where the real upside is. But it’s only 12% of the portfolio right now.
CDMO Sites15Global. Mostly idle capacity.
CDMO Customers~500Deep relationships. Fickle funding.
CHG Sevo Share (US)45%Market leader. Regulatory delays.
Consumer Growth Q3+20%The only engine running.
The Kenalog Play: Piramal is acquiring Triamcinolone Acetonide (Kenalog) from BMS for $35M upfront + up to $65M contingent. $30–40M annual revenue expected. Complex injectable corticosteroid. Limited competition due to “manufacturing complexities.” Will leverage existing hospital channel. Management is framing this as a “cash contributor” and “not expecting this to be a grower.” Translation: It’s defensive consolidation dressed up as strategy.
💬 Does a ₹22.5% stock decline mean undervaluation, or a justified repricing of execution risk? What’s your read — contrarian opportunity or a slow-motion train wreck?
04 — Financials Overview
Q3 FY26: The Numbers That Keep You Up At Night
Result type: Quarterly Results (Consolidated) | Q3 FY26 EPS: -₹1.02 | 9M FY26 EPS: -₹2.40 (accumulated) | No positive earnings for annualisation
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 2,140 | 2,204 | 2,044 | -2.9% | +4.7% |
| EBITDA | 196 | 338 | 159 | -42.0% | +23.3% |
| EBITDA Margin % | 9% | 15% | 8% | -600 bps | +100 bps |
| Net Loss | -136 | +4 | -99 | Loss | Loss widened |
| EPS (₹) | -1.02 | +0.03 | -0.75 | Loss | Loss widened |
The Arithmetic Is Brutal: Q3 FY26 revenue of ₹2,140 crore is down 2.9% YoY (₹2,204 crore in Q3 FY25). EBITDA collapsed 42% to ₹196 crore. But here’s the comedy: they’re still paying ₹89 crore in interest, ₹213 crore in depreciation. Operating profit of ₹196 crore minus all that = ₹-94 crore before tax. Post-tax, it’s ₹-136 crore loss. Nine months consolidated: ₹6,117 crore revenue, ₹-317 crore net loss. ROCE of 6.45% is lower than FD rates. P/E doesn’t exist because there’s no earnings. This is a balance-sheet deterioration story masquerading as a cyclical downturn.
05 — Valuation Discussion: Fair Value Range
What’s This Wreck Actually Worth?
Join 10,000+ investors who read this every week.
